Vigeo Therapeutics

Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents for the treatment of advanced malignancies, effectively addressing various cancers and improving patients' lives. The company has established a first-class drug discovery pipeline to reprogram the tumor immune microenvironment (TIME) and is currently advancing therapies targeting TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumor protein and a defense mechanism of the human body against cancer. Tsp-1 has been shown to attack cancer cells and prevent their metastatic spread via the CD36 and CD47 pathways.